Breast Neoplasms
📧 Sign up to get email alerts when something new happens for Breast Neoplasms.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-28EMA Authorised: Herzuma (trastuzumab) — Celltrion Healthcare Hungary Kft.
Authorised status for Herzuma (trastuzumab) in the European market for stomach and breast neoplasms.
-
EMA approval · 2026-08-25EMA Authorised: Verzenios (abemaciclib) — Eli Lilly Nederland B.V.
Authorised status for Verzenios (abemaciclib) in the EU for treatment of breast neoplasms.
-
EMA approval · 2026-08-19EMA Authorised: Kisqali (ribociclib succinate) — Novartis Europharm Limited
Kisqali (ribociclib succinate) has been authorised by the EMA for use in breast neoplasms.
-
EMA approval · 2026-08-18EMA Authorised: Tuznue (trastuzumab) — Prestige Biopharma Belgium
Authorization granted for Tuznue (trastuzumab) by EMA for breast neoplasms.
-
EMA approval · 2026-08-18EMA Authorised: Herwenda (trastuzumab) — Sandoz GmbH
Authorised trastuzumab product Herwenda by Sandoz GmbH for breast and stomach neoplasms in the EU.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-08-12EMA Authorised: Lynparza (olaparib) — AstraZeneca AB
Olaparib (Lynparza) has been authorised by the EMA for multiple indications across ovarian, breast, pancreatic, and castration-resistant pro…
-
EMA approval · 2026-08-11EMA Authorised: Kanjinti (trastuzumab) — Amgen Europe B.V.
EMA authorises Kanjinti (trastuzumab) for indications including stomach and breast neoplasms.
-
EMA approval · 2026-08-06EMA Authorised: Docetaxel Kabi (docetaxel) — Fresenius Kabi Deutschland GmbH
EU authorization of Docetaxel Kabi (docetaxel) for multiple cancer indications including head and neck neoplasms, non-small cell lung carcin…
-
EMA approval · 2026-08-04EMA Authorised: Orserdu (elacestrant) — Stemline Therapeutics B.V.
EMA authorised Orserdu (elacestrant) for breast neoplasms, marking approval under Stemline Therapeutics B.V. as MAH.
-
EMA approval · 2026-07-28EMA Authorised: Trodelvy (sacituzumab govitecan) — Gilead Sciences Ireland UC
Trodelvy (sacituzumab govitecan) has been authorised by the EMA for breast cancer indications including triple-negative breast cancer.
-
EMA approval · 2026-07-21EMA Authorised: Etcamah (camizestrant) — AstraZeneca AB
Etcamah (camizestrant) has been authorised by EMA for the therapeutic area of breast neoplasms.
-
EMA approval · 2026-07-21EMA Authorised: Tecentriq (atezolizumab) — Roche Registration GmbH
Roche's Tecentriq (atezolizumab) has been authorised by the EMA for multiple indications including transitional cell carcinoma, non-small ce…
-
EMA approval · 2026-07-17EMA Authorised: Enhertu (trastuzumab deruxtecan) — Daiichi Sankyo Europe GmbH
Enhertu (trastuzumab deruxtecan) has been authorised by the EMA for breast neoplasms under conditional approval.
-
EMA approval · 2026-07-16EMA Authorised: Trodelvy (sacituzumab govitecan) — Gilead Sciences Ireland UC
EMA authorised Trodelvy (sacituzumab govitecan) for breast neoplasms, including triple negative breast neoplasms, with Gilead Sciences Irela…
-
EMA approval · 2026-07-14EMA Authorised: Tuznue (trastuzumab) — Prestige Biopharma Belgium
Tuznue (trastuzumab) has been authorised in Europe for breast neoplasms.
-
EMA approval · 2026-07-08EMA Authorised: Trazimera (trastuzumab) — Pfizer Europe MA EEIG
Authorised status for Trazimera (trastuzumab) by Pfizer Europe MA EEIG in the EMA system for use in stomach and breast neoplasms.
-
EMA approval · 2026-07-07EMA Authorised: Abevmy (bevacizumab) — Biosimilar Collaborations Ireland Limited
EMA authorises a biosimilar version of bevacizumab (Abevmy) for multiple cancer indications, expanding access to this biologic therapy.
-
EMA approval · 2026-07-06EMA Authorised: Enhertu (trastuzumab deruxtecan) — Daiichi Sankyo Europe GmbH
EMA authorises Enhertu (trastuzumab deruxtecan) for breast neoplasms with conditional approval.
-
EMA approval · 2026-06-16EMA Authorised: Kadcyla (trastuzumab emtansine) — Roche Registration GmbH
Kadcyla (trastuzumab emtansine) by Roche Registration GmbH has been authorised for use in the European Union for breast neoplasms.
-
EMA approval · 2026-06-03EMA Authorised: Lynparza (olaparib) — AstraZeneca AB
Olaparib (Lynparza) has been authorised by the EMA for multiple neoplasms including ovarian, breast, pancreatic, and castration-resistant pr…
-
EMA approval · 2026-04-28EMA Authorised: Perjeta (pertuzumab) — Roche Registration GmbH
European Medicines Agency authorises Perjeta (pertuzumab) for use in breast neoplasms.
-
EMA approval · 2026-04-28EMA Authorised: Dazublys (trastuzumab) — CuraTeQ Biologics s.r.o
Authorised monoclonal antibody therapy trastuzumab (Dazublys) for breast and stomach neoplasms in the EU.
-
EMA approval · 2026-04-28EMA Authorised: Tecentriq (atezolizumab) — Roche Registration GmbH
Authorised status for Tecentriq (atezolizumab) by Roche Registration GmbH across multiple cancer indications in the European market.
-
EMA approval · 2026-03-02EMA Authorised: Herceptin (trastuzumab) — Roche Registration GmbH
The EMA authorised Herceptin (trastuzumab) for stomach neoplasms and breast neoplasms. The marketing authorization holder is Roche Registrat…
-
EMA approval · 2026-02-24EMA Authorised: Eribulin Baxter (Eribulin mesylate) — Baxter Holding B.V.
EMA authorised Eribulin Baxter (eribulin mesylate) for treatment of breast neoplasms and liposarcoma; the marketing authorisation holder is …